person · Reporting owner

Miller Vincent A.

Disclosed activity across 2 companies

Tapewire entity: 137924
SEC CIK: 0001584999

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Revolution Medicines, Inc.RVMD · Entity 606	Director	June 22, 2021	June 24, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Revolution Medicines, Inc.

Report date June 22, 2021 · Filed June 24, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,750	Reported balance After 2021-06-22 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-06-22 · Grant · Acquired 3,617 · Balance 23,750 F1: Includes 3,617 Restricted Stock Units.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.93 · Expires 2031-06-21	Direct	12,659	Reported balance After 2021-06-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-22 · Grant · Acquired 12,659 · Balance 12,659 F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 22, 2021 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 3,617 Restricted Stock Units.

F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 22, 2021 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Foundation Medicine, Inc.

Report date July 31, 2018 · Filed August 02, 2018

Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2018-07-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-07-31 · Other · Disposed 30,993 · Balance 36,186 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Row 2 · 2018-07-31 · Other · Disposed 36,186 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.
stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.94 · Expires 2024-04-09	Direct	0	Reported balance After 2018-07-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-07-31 · Other · Disposed 14,271 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes. F5: Represents the non-qualified portion of a stock option granted on April 9, 2014 with vesting in equal quarterly installments beginning on June 30, 2014 until fully vested on March 31, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.

F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.

F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.

F4: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes.

F5: Represents the non-qualified portion of a stock option granted on April 9, 2014 with vesting in equal quarterly installments beginning on June 30, 2014 until fully vested on March 31, 2018.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 22, 2021 Filed Jun 24, 2021 17:19 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	12,659	$0.00 Strike: $32.93	$0.00	Disclosure SEC source: 0001567619-21-012594 · doc1.xml · derivative · entry 2 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,659 Underlying: Common Stock · 12,659 shares Expires 2031-06-21 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 22, 2021 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document
June 22, 2021 Filed Jun 24, 2021 17:19 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	3,617	$0.00	$0.00	Disclosure SEC source: 0001567619-21-012594 · doc1.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,750 F1 · balance_after: Includes 3,617 Restricted Stock Units. Read SEC document
March 22, 2021 Filed Mar 24, 2021 18:11 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	1,600	$0.00 Strike: $4.73	$0.00	Disclosure SEC source: 0001567619-21-006887 · doc1.xml · derivative · entry 4 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,785 Underlying: Common Stock · 1,600 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is early exercisable. One twelfth (1/12th) of the shares initially subject to the option will vest on each monthly anniversary measured from September 27, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the first anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
March 22, 2021 Filed Mar 24, 2021 18:11 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	1,600	$0.00 Strike: $4.73	$0.00	Disclosure SEC source: 0001567619-21-006887 · doc1.xml · derivative · entry 3 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,397 Underlying: Common Stock · 1,600 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is early exercisable. One twenty-fourth (1/24th) of the shares initially subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
March 22, 2021 Filed Mar 24, 2021 18:11 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	3,200	$49.00	$156,800.00	Disclosure SEC source: 0001567619-21-006887 · doc1.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,133 F1 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document
March 22, 2021 Filed Mar 24, 2021 18:11 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	3,200	$4.73	$15,136.00	Disclosure SEC source: 0001567619-21-006887 · doc1.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document
October 06, 2020 Filed Oct 8, 2020 17:07 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	6,250	$39.00	$243,750.00	Disclosure SEC source: 0001567619-20-017694 · doc1.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,133 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document
September 29, 2020 Filed Sep 30, 2020 20:33 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	450	$34.07	$15,332.49	Disclosure SEC source: 0001567619-20-017293 · doc1.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,383 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document
September 28, 2020 Filed Sep 30, 2020 20:33 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,300	$34.11	$180,772.40	Disclosure SEC source: 0001567619-20-017293 · doc1.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,833 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document
September 23, 2020 Filed Sep 25, 2020 16:29 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	500	$34.02	$17,010.00	Disclosure SEC source: 0001567619-20-017108 · doc1.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,133 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $34.00 to $34.0650, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document
June 17, 2020 Filed Jun 19, 2020 15:36 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	6,329	$0.00 Strike: $36.57	$0.00	Disclosure SEC source: 0001567619-20-012446 · doc1.xml · derivative · entry 2 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,329 Underlying: Common Stock · 6,329 shares Expires 2030-06-16 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 17, 2020 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document
June 17, 2020 Filed Jun 19, 2020 15:36 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	1,808	$0.00	$0.00	Disclosure SEC source: 0001567619-20-012446 · doc1.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,633 F1 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:07 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Otherstock option (right to buy) · Derivative	14,271	$0.00 Strike: $29.94	$0.00	Disclosure SEC source: 0001209191-18-044931 · doc4.xml · derivative · entry 3 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,271 shares Expires 2024-04-09 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4 · shares: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes. F5 · derivative.exercise_date: Represents the non-qualified portion of a stock option granted on April 9, 2014 with vesting in equal quarterly installments beginning on June 30, 2014 until fully vested on March 31, 2018. Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:07 UTC	Foundation Medicine, Inc. FMI · Entity 164565	OtherCommon Stock	36,186	$137.00	$4,957,482.00	Disclosure SEC source: 0001209191-18-044931 · doc4.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3 · shares: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units. Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:07 UTC	Foundation Medicine, Inc. FMI · Entity 164565	OtherCommon Stock	30,993	$137.00	$4,246,041.00	Disclosure SEC source: 0001209191-18-044931 · doc4.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,186 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2 · shares: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Read SEC document
July 02, 2018 Filed Jul 5, 2018 16:09 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	2,909	$136.66	$397,543.94	Disclosure SEC source: 0001209191-18-041552 · doc4.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,179 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on (1) April 1, 2016 in Table I of the Form 4 filed on April 6, 2016, (2) May 1, 2017 in Table I of the Form 4 filed on May 3, 2017 and (3) April 1, 2018 in Table I of the Form 4 filed on April 3, 2018. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting events related to this securities sale. Read SEC document
May 21, 2018 Filed May 23, 2018 16:06 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionStock Option (right to buy) · Derivative	1,570	$0.00 Strike: $29.94	$0.00	Disclosure SEC source: 0001209191-18-032563 · doc4.xml · derivative · entry 3 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,570 shares Expires 2024-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This stock option was granted on April 9, 2014 and vested in equal quarterly installments beginning on June 30, 2014 until fully vested on March 31, 2018. Read SEC document
May 21, 2018 Filed May 23, 2018 16:06 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1,570	$85.00	$133,450.00	Disclosure SEC source: 0001209191-18-032563 · doc4.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,088 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. Read SEC document
May 21, 2018 Filed May 23, 2018 16:06 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	1,570	$29.94	$47,005.80	Disclosure SEC source: 0001209191-18-032563 · doc4.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 16, 2018 Filed Apr 18, 2018 16:07 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	3,283	$74.02	$243,007.66	Disclosure SEC source: 0001209191-18-025354 · doc4.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,088 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.00 to $78.20, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
April 02, 2018 Filed Apr 3, 2018 16:11 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	2,529	$74.86	$189,320.94	Disclosure SEC source: 0001209191-18-022889 · doc4.xml · nonDerivative · entry 3 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,371 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F5 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.60 to $75.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F6 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
April 02, 2018 Filed Apr 3, 2018 16:11 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	354	$75.00	$26,550.00	Disclosure SEC source: 0001209191-18-022889 · doc4.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,900 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on March 31, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F3 · balance_after: The reporting person previously reported all restricted stock units granted to the reporting person on April 9, 2014 in Table I of the Form 4/A filed on May 27, 2014. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect this vesting event. Read SEC document
April 01, 2018 Filed Apr 3, 2018 16:11 UTC	Foundation Medicine, Inc. FMI · Entity 164565	GrantCommon Stock	12,932	$78.75	$1,018,395.00	Disclosure SEC source: 0001209191-18-022889 · doc4.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,254 F1 · shares: Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in equal quarterly installments over a three-year period with the first installment vesting on July 1, 2018. Read SEC document
March 09, 2018 Filed Mar 12, 2018 16:15 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionStock Option (right to buy) · Derivative	6,811	$0.00 Strike: $29.94	$0.00	Disclosure SEC source: 0001209191-18-018862 · doc4.xml · derivative · entry 4 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,570 Underlying: Common Stock · 6,811 shares Expires 2024-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on April 9, 2014 and vests in equal quarterly installments beginning on June 30, 2014 until fully vested on March 31, 2018. Read SEC document
March 09, 2018 Filed Apr 3, 2018 16:12 UTC Amendment	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionStock Option (right to buy) · Derivative	6,811	$0.00 Strike: $29.94	$0.00	Disclosure SEC source: 0001209191-18-022893 · doc4a.xml · derivative · entry 4 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,570 Underlying: Common Stock · 6,811 shares Expires 2024-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on April 9, 2014 and vests in equal quarterly installments beginning on June 30, 2014 until fully vested on March 31, 2018. Read SEC document
March 09, 2018 Filed Apr 3, 2018 16:12 UTC Amendment	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	10,000	$85.00	$850,000.00	Disclosure SEC source: 0001209191-18-022893 · doc4a.xml · nonDerivative · entry 3 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. Read SEC document
March 09, 2018 Filed Apr 3, 2018 16:12 UTC Amendment	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	6,811	$85.00	$578,935.00	Disclosure SEC source: 0001209191-18-022893 · doc4a.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. Read SEC document
March 09, 2018 Filed Apr 3, 2018 16:12 UTC Amendment	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	6,811	$29.94	$203,921.34	Disclosure SEC source: 0001209191-18-022893 · doc4a.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 20, 2018 Filed Feb 22, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionStock Option (right to guy) · Derivative	9,375	$0.00 Strike: $7.12	$0.00	Disclosure SEC source: 0001209191-18-012313 · doc4.xml · derivative · entry 7 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,375 shares Expires 2023-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option was granted on May 21, 2013 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018. Read SEC document
February 20, 2018 Filed Feb 22, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionStock Option (right to buy) · Derivative	2,633	$0.00 Strike: $4.16	$0.00	Disclosure SEC source: 0001209191-18-012313 · doc4.xml · derivative · entry 6 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,633 shares Expires 2023-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on March 7, 2013 and vested in equal quarterly installments beginning on June 7, 2013 until fully vested on March 7, 2017. Read SEC document
February 20, 2018 Filed Feb 22, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	20,000	$76.87	$1,537,400.00	Disclosure SEC source: 0001209191-18-012313 · doc4.xml · nonDerivative · entry 5 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.15 to $78.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
February 20, 2018 Filed Feb 22, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	9,375	$76.87	$720,656.25	Disclosure SEC source: 0001209191-18-012313 · doc4.xml · nonDerivative · entry 4 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.15 to $78.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
February 20, 2018 Filed Feb 22, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	9,375	$7.12	$66,750.00	Disclosure SEC source: 0001209191-18-012313 · doc4.xml · nonDerivative · entry 3 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 20, 2018 Filed Feb 22, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	2,633	$76.87	$202,398.71	Disclosure SEC source: 0001209191-18-012313 · doc4.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.15 to $78.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
February 20, 2018 Filed Feb 22, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	2,633	$4.16	$10,953.28	Disclosure SEC source: 0001209191-18-012313 · doc4.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 20, 2018 Filed Mar 12, 2018 16:15 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	10,000	$85.00	$850,000.00	Disclosure SEC source: 0001209191-18-018862 · doc4.xml · nonDerivative · entry 3 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. Read SEC document
February 20, 2018 Filed Mar 12, 2018 16:15 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	6,811	$85.00	$578,935.00	Disclosure SEC source: 0001209191-18-018862 · doc4.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. Read SEC document
February 20, 2018 Filed Mar 12, 2018 16:15 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	6,811	$29.94	$203,921.34	Disclosure SEC source: 0001209191-18-018862 · doc4.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 29, 2018 Filed Jan 31, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionStock Option (right to buy) · Derivative	4,400	$0.00 Strike: $4.16	$0.00	Disclosure SEC source: 0001209191-18-006186 · doc4.xml · derivative · entry 3 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,633 Underlying: Common Stock · 4,400 shares Expires 2023-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on March 7, 2013 and vested in equal quarterly installments beginning on June 7, 2013 until fully vested on March 7, 2017. Read SEC document
January 29, 2018 Filed Jan 31, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	4,400	$75.00	$330,000.00	Disclosure SEC source: 0001209191-18-006186 · doc4.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. Read SEC document
January 29, 2018 Filed Jan 31, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	4,400	$4.16	$18,304.00	Disclosure SEC source: 0001209191-18-006186 · doc4.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 22, 2018 Filed Jan 24, 2018 16:19 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionStock Option (right to buy) · Derivative	17,187	$0.00 Strike: $0.84	$0.00	Disclosure SEC source: 0001209191-18-005100 · doc4.xml · derivative · entry 3 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,187 shares Expires 2022-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on January 10, 2012 and vested in equal quarterly installments beginning on December 31, 2013 until fully vested on April 8, 2016. Read SEC document
January 22, 2018 Filed Jan 24, 2018 16:19 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	17,187	$70.27	$1,207,730.49	Disclosure SEC source: 0001209191-18-005100 · doc4.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.00 to $71.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
January 22, 2018 Filed Jan 24, 2018 16:19 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	17,187	$0.84	$14,437.08	Disclosure SEC source: 0001209191-18-005100 · doc4.xml · nonDerivative · entry 1 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 17, 2018 Filed Jan 18, 2018 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionStock Option (right to buy) · Derivative	5,534	$0.00 Strike: $0.84	$0.00	Disclosure SEC source: 0001209191-18-004229 · doc4.xml · derivative · entry 7 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,534 shares Expires 2022-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on January 10, 2012 and vested in equal quarterly installments beginning on December 31, 2012 until fully vested on April 8, 2016. Read SEC document
January 17, 2018 Filed Jan 18, 2018 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	5,534	$65.39	$361,868.26	Disclosure SEC source: 0001209191-18-004229 · doc4.xml · nonDerivative · entry 5 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F3 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.00 to $66.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
January 17, 2018 Filed Jan 18, 2018 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	5,534	$0.84	$4,648.56	Disclosure SEC source: 0001209191-18-004229 · doc4.xml · nonDerivative · entry 4 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 18, 2018 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionStock Option (right to buy) · Derivative	5,408	$0.00 Strike: $0.84	$0.00	Disclosure SEC source: 0001209191-18-004229 · doc4.xml · derivative · entry 6 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,534 Underlying: Common Stock · 5,408 shares Expires 2022-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on January 10, 2012 and vested in equal quarterly installments beginning on December 31, 2012 until fully vested on April 8, 2016. Read SEC document
January 16, 2018 Filed Jan 18, 2018 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	5,408	$65.26	$352,926.08	Disclosure SEC source: 0001209191-18-004229 · doc4.xml · nonDerivative · entry 3 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,322 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.15 to $68.75, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
January 16, 2018 Filed Jan 18, 2018 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	5,408	$0.84	$4,542.72	Disclosure SEC source: 0001209191-18-004229 · doc4.xml · nonDerivative · entry 2 Miller Vincent A. · CIK 0001584999 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.